We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Morphotek® Announces Evaluation Agreement with the University Hospital Heidelberg
News

Morphotek® Announces Evaluation Agreement with the University Hospital Heidelberg

Morphotek® Announces Evaluation Agreement with the University Hospital Heidelberg
News

Morphotek® Announces Evaluation Agreement with the University Hospital Heidelberg

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Morphotek® Announces Evaluation Agreement with the University Hospital Heidelberg"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced the signing of an evaluation agreement with the University Hospital Heidelberg and its Technology Transfer Office, Germany to advance the company's efforts in the discovery and development of therapeutic antibodies in oncology.

The agreement provides for a research grant to the University Hospital/National Center for Tumor Diseases (NCT) and for use by Morphotek of biological materials to generate and validate therapeutic monoclonal antibodies to oncology targets selected by Morphotek.

“We are very pleased to be collaborating with one of the world’s leading research and clinical centers in oncology,” said Nicholas Nicolaides, Ph.D., President and CEO of Morphotek.

“This research program offers Morphotek unique clinical materials to generate and validate potential therapeutic antibodies using our MORPHODOMA® technologies and will enable us to advance our goal of discovering and developing novel monoclonal antibody therapeutics. The clinical group at NCT is dedicated to bringing new therapies to treat patients with cancer, and we look forward to collaborating with them to discover new experimental medicines with potential to treat patients with various cancers.”
Advertisement